Skip to main content
HYUNDAI PHARMACEUTICAL CO., LTD logo

HYUNDAI PHARMACEUTICAL CO., LTD — Investor Relations & Filings

Ticker · 004310 ISIN · KR7004310009 KO Manufacturing
Filings indexed 184 across all filing types
Latest filing 2022-02-08 AGM Information
Country KR South Korea
Listing KO 004310

About HYUNDAI PHARMACEUTICAL CO., LTD

http://www.hyundaipharm.co.kr/english

HYUNDAI PHARMACEUTICAL CO., LTD. is a company engaged in the research, development, manufacturing, and distribution of pharmaceutical products, medical devices, and health-focused food and beverages. The company's portfolio encompasses a broad range of prescription (ETC) and over-the-counter (OTC) medicines. Key therapeutic areas include dermatology, respiratory and gastrointestinal disorders, as well as treatments for conditions such as hypertension and dementia. With a strong commitment to innovation, the company focuses on the research of new substances and the continuous development of its drug pipeline. It also serves as a strategic partner for global companies, facilitating market entry and collaboration through its business development initiatives.

Recent filings

Filing Released Lang Actions
주주총회소집결의
AGM Information Classification · 98% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) issued by Hyundai Pharm. It outlines the date, location, and specific agenda items (financial statement approval, director appointments, etc.) for the upcoming meeting. This type of document is sent to shareholders to provide information and request their participation/votes, which aligns with the definition of a Proxy Solicitation & Information Statement.
2022-02-08 Korean
매출액또는손익구조30%(대규모법인은15%)이상변경
Earnings Release Classification · 100% confidence The document is a formal regulatory filing from Hyundai Pharm regarding a significant change in financial structure (revenue/profit/loss) exceeding 30%. It provides preliminary financial results (sales, operating profit, net income) and explains the reasons for the changes (e.g., clinical trial suspension). This is a standard periodic financial disclosure announcement required by stock exchanges, which falls under the 'Earnings Release' category as it provides the initial summary of financial performance before the final audited report. FY 2021
2022-01-10 Korean
분기보고서 (2021.08)
Interim / Quarterly Report Classification · 100% confidence The document is a '분기보고서' (Quarterly Report) for Hyundai Pharmaceutical Co., Ltd. for the 3rd quarter of the 58th fiscal year (covering 2020-12-01 to 2021-08-31). It contains detailed financial data, business operations, management discussions, and governance information, which aligns with the definition of an Interim/Quarterly Report (IR). 9M 2021
2021-10-15 Korean
기타경영사항(자율공시)
Regulatory Filings Classification · 95% confidence The document is a voluntary disclosure (자율공시) from Hyundai Pharm regarding the results of a Phase 3 clinical trial for the drug 'Bumetanide'. It details the clinical trial outcome, the failure to meet efficacy endpoints, and future plans. Since this is a regulatory announcement regarding a specific corporate event (clinical trial results) that does not fit into financial reporting or other specific categories like M&A or dividends, it falls under the general regulatory filing category.
2021-09-13 Korean
반기보고서 (2021.05)
Interim / Quarterly Report Classification · 100% confidence The document is a '반기보고서' (Semi-annual Report) for Hyundai Pharmaceutical Co., Ltd. for the 58th fiscal period (covering 2020-12-01 to 2021-05-31). It contains comprehensive financial information, business descriptions, organizational structure, and management details. As it is a comprehensive financial report for a period shorter than a full fiscal year (half-year) and contains substantive financial data, it is classified as an Interim/Quarterly Report. H1 2021
2021-07-15 Korean
[기재정정]반기보고서 (2021.05)
Interim / Quarterly Report Classification · 100% confidence The document is a '반기보고서' (Semi-annual Report) for Hyundai Pharm Co., Ltd. for the 58th fiscal period. It contains detailed financial statements, management discussions, business operations, and governance information. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). H1 2021
2021-07-15 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.